Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROBAXIN-750 vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
750 mg orally four times daily (total daily dose 3000 mg).
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Hepatic metabolism via dealkylation and hydroxylation, primarily by cytochrome P450 enzymes; metabolites are excreted renally.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
46-50% (primarily to albumin); binding is reversible and non-saturable at therapeutic concentrations.
Approximately 90–95% bound, primarily to albumin.
0.9-1.5 L/kg (apparent Vd); clinical meaning: indicates extensive distribution into total body water and tissues, including muscle.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: about 50-75% (due to first-pass metabolism); bioavailability may vary with food (high-fat meal reduces rate but not extent).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
GFR 30-50 m L/min: administer 750 mg every 8 hours; GFR <30 m L/min: avoid use or administer with extreme caution; not studied in dialysis.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 30-50% (e.g., 375-500 mg q6h); Child-Pugh Class C: contraindicated due to risk of hepatic encephalopathy.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Not recommended for pediatric use; safety and efficacy not established.
Not established; safety and efficacy not studied in pediatric patients.
Initiate at low end of dosing range (e.g., 375 mg q6h) due to increased risk of sedation and falls; monitor renal function and CNS effects.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
None
None
May cause drowsiness, dizziness, or blurred vision; patients should not operate machinery or drive until effects are known.,Use with caution in patients with known drug sensitivities or allergies.,May impair mental and/or physical abilities.,Seizures have been reported in patients with underlying seizure disorders or concurrent use of CNS depressants.,Serotonergic effects may occur with concurrent use of serotonergic drugs.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to methocarbamol or any component of the formulation.,Patients with known or suspected myasthenia gravis.,Patients with renal impairment (due to propylene glycol content in the injectable form; oral formulation does not contain propylene glycol but should be used cautiously).
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Take with food to reduce gastrointestinal upset. Avoid alcohol during treatment. No specific food restrictions.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
FDA Category C: Methocarbamol has shown fetal toxicity (reduced fetal weight, increased skeletal variations) in animal studies at doses similar to human doses. First trimester: Insufficient human data; avoid unless clearly needed. Second/third trimester: Limited data; potential for musculoskeletal effects. Use only if benefit outweighs risk.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Methocarbamol is excreted into breast milk in small amounts; M/P ratio not established. The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for sedation or muscle weakness.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No specific dose adjustments recommended based on pharmacokinetic changes in pregnancy. Use lowest effective dose; IV administration should be cautious due to increased plasma volume and risk of hypotension.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
ROBAXIN-750 (methocarbamol 750 mg) is a centrally acting muscle relaxant. It does not directly relax skeletal muscle but acts via CNS depression. Onset of action is ~30 minutes; peak effect at 2 hours. It is often used with rest, physical therapy, and NSAIDs. Contraindicated in myasthenia gravis. Doses exceeding 6 g/day may cause severe adverse effects. Tablet contains FD&C Yellow No. 5 (tartrazine), which may cause allergic reactions in susceptible individuals.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase sedation.,Notify your doctor if you have myasthenia gravis, allergies to tartrazine (FD&C Yellow No. 5), or if you are pregnant or breastfeeding.,May discolor urine (brown, black, or blue-green); this is harmless.,Do not stop suddenly; withdrawal symptoms (e.g., anxiety, insomnia) may occur with abrupt discontinuation after prolonged use.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROBAXIN-750 vs CHLORZOXAZONE, answered by our medical review team.
ROBAXIN-750 is a Skeletal Muscle Relaxant that works by Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROBAXIN-750 and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROBAXIN-750 is: 750 mg orally four times daily (total daily dose 3000 mg).. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROBAXIN-750 and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROBAXIN-750 is classified as Category C. FDA Category C: Methocarbamol has shown fetal toxicity (reduced fetal weight, increased skeletal variations) in animal studies at doses similar to human doses. First trimester: Ins. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.